NVOH - ETF AI Analysis
Top Page
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
Rating:70Outperform
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges relatively low annual fees, which helps investors keep more of their returns over time.
Clear, Focused Strategy
The ETF is tightly focused on a single leading healthcare company, making it easy to understand what you are investing in.
Recent Short-Term Rebound
The ETF has shown a strong gain over the past month, suggesting some recovery after earlier weakness.
Negative Factors
Extreme Single-Stock Concentration
Almost the entire fund is invested in one company, which greatly increases the risk if that stock performs poorly.
Recent Weak Overall Performance
The ETF’s returns so far this year and over the last few months have been weak, reflecting pressure on its main holding.
Lack of Diversification by Sector and Region
The fund is heavily concentrated in the U.S. healthcare sector, offering little protection if that area of the market struggles.
NVOH vs. SPDR S&P 500 ETF (SPY)
AUM4.31M
RegionEurope
Expense Ratio0.19%
Beta1.13
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield4.17%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,003
30 Day Avg. Volume5,469
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
22.43Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NVOH Summary
NVOH is an ETF that focuses almost entirely on Novo Nordisk, a major global healthcare and pharmaceutical company known for its diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to this single leader in the health care and pharmaceuticals space, while using a currency hedge to reduce the impact of foreign exchange swings for U.S. investors. Someone might invest for potential long-term growth tied to rising demand for treatments of chronic diseases. A key risk is that the fund is concentrated in one company, so its value can rise or fall sharply with Novo Nordisk’s fortunes.
How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.
What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.
NVOH Top 10 Holdings
This ETF is essentially a one-stock story, with Novo Nordisk doing almost all the heavy lifting. The Danish pharma giant has been rising in the very short term, but its recent few months have been choppy, with the stock losing steam after earlier strength. That means the fund’s performance is tightly tied to how investors feel about Novo’s diabetes and obesity franchise on any given day. Sector-wise, it’s a pure health care and pharmaceuticals play, and geographically it’s firmly anchored in Europe, with all roads leading back to Denmark.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 96.32% | $4.12M | $181.09B | -34.21% | 73 Outperform |
NVOH Technical Analysis
Neutral
―
Price Trends
21.19
Positive
24.73
Negative
26.77
Negative
Market Momentum
0.30
Negative
57.05
Neutral
79.38
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 21.51, equal to the 50-day MA of 21.19, and equal to the 200-day MA of 26.77, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 57.05 is Neutral, neither overbought nor oversold. The STOCH value of 79.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVOH.
NVOH Peer Comparison
Comparison Results
Performance Comparison
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
22.26
-12.78
-36.47%
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
STHH
STMicroelectronics NV ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents